Micron Biomedical, a clinical-stage biotechnology company advancing needle-free vaccines and therapeutics, has appointed Elizabeth Holmberg as Chief Financial Officer as part of the company’s efforts toward commercialization of its proprietary dissolvable drug delivery platform and products. Recently, the company celebrated the grand opening of its commercial-scale manufacturing site in Georgia and was chosen by the CDC for its first clinical trial of a needle-free vaccine. Research presented this year, reflecting parents are more likely to vaccinate their children with a pain-free option, builds on data published in the Lancet about Micron’s self-administered seasonal influenza vaccine in the US and measles/rubella vaccine in the Gambia.
Micron Biomedical, a clinical-stage biotechnology company advancing needle-free vaccines and therapeutics, has appointed Elizabeth Holmberg as Chief Financial Officer as part of the company’s efforts toward commercialization of its proprietary dissolvable drug delivery platform and products. Recently, the company celebrated the grand opening of its commercial-scale manufacturing site in Georgia and was chosen by the CDC for its first clinical trial of a needle-free vaccine. Research presented this year, reflecting parents are more likely to vaccinate their children with a pain-free option, builds on data published in the Lancet about Micron’s self-administered seasonal influenza vaccine in the US and measles/rubella vaccine in the Gambia.